Goat Anti-Human IgM mu chain (HRP) (ab97205)
Key features and details
- Goat Anti-Human IgM mu chain (HRP)
- Conjugation: HRP
- Host species: Goat
- Isotype: IgG
- Suitable for: ICC, IHC-P, ELISA, WB
Related conjugates and formulations
製品の概要
-
製品名
Goat Anti-Human IgM mu chain (HRP)
IgM 二次抗体 製品一覧 -
由来種
Goat -
ターゲット生物種
Human -
特異性
By immunoelectrophoresis and ELISA this antibody reacts specifically with Human IgM. Cross reactivity with other immunoglobulins and light chains is less than 0.1%. -
アプリケーション
適用あり: ICC, IHC-P, ELISA, WBmore details -
標識
HRP
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C. -
バッファー
pH: 6.8
Constituents: 0.2% BSA, 0.05% CMIT/MIT based preservative -
Concentration information loading...
-
精製度
Immunogen affinity purified -
特記事項(精製)
Antiserum was solid phase adsorbed to ensure class specificity. This antibody was isolated by affinity chromatography using antigen coupled to agarose beads and conjugated to Horse Radish Peroxidase (HRP). -
特記事項(標識)
Molar enzyme/ antibody protein ratio is 4:1 -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab97205の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
ICC |
Use at an assay dependent dilution.
|
|
IHC-P |
1/200 - 1/2000.
|
|
ELISA |
1/10000 - 1/100000. (as Primary).
|
|
WB |
1/2000 - 1/25000. Colorimetric: 1/2000 - 1/20000; Chemiluminescent: 1/5000 - 1/25000
|
特記事項 |
---|
ICC
Use at an assay dependent dilution. |
IHC-P
1/200 - 1/2000. |
ELISA
1/10000 - 1/100000. (as Primary). |
WB
1/2000 - 1/25000. Colorimetric: 1/2000 - 1/20000; Chemiluminescent: 1/5000 - 1/25000 |
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (20)
ab97205 は 20 報の論文で使用されています。
- Liu Y et al. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nat Commun 14:2179 (2023). PubMed: 37069158
- Gonçalves J et al. Balance between maternal antiviral response and placental transfer of protection in gestational SARS-CoV-2 infection. JCI Insight 8:N/A (2023). PubMed: 37490342
- Canto E Castro L et al. Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection. Eur J Immunol 52:149-160 (2022). PubMed: 34695227
- Ranjbar M et al. Development of a recombinant nucleocapsid protein-based ELISA for the detection of IgM and IgG antibodies to SARS-CoV-2. Biotechnol Appl Biochem 69:2592-2598 (2022). PubMed: 34965611
- Su Y et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185:881-895.e20 (2022). PubMed: 35216672